Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.31 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.31 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549239 | 0.91 | BTK (0.42) | SYKBTKKDRKCNN1KCNN2 | |
| SCHEMBL24549464 | 0.90 | SYK (0.37) | SYKBTKKCNH2KDRKCNN1 | |
| SCHEMBL29653718 | 0.90 | SYK (0.37) | SYKBTKKCNH2KDRKCNN1 | |
| SCHEMBL24549232 | 0.89 | KCNH2 (0.44) | SYKBTKKCNH2KDR | |
| SCHEMBL24549235 | 0.89 | SYK (0.38) | SYKBTKKCNH2KDRSOS1 | |
| SCHEMBL29653762 | 0.89 | SYK (0.36) | SYKBTKKCNH2KDRPTGES | |
| SCHEMBL24548979 | 0.89 | SYK (0.36) | SYKBTKKCNH2KDRPTGES | |
| SCHEMBL24548986 | 0.87 | SYK (0.37) | SYKBTKKCNH2KDRPTGES | |
| SCHEMBL24549099 | 0.87 | PRKAB2 (0.43) | BTKPOLB | |
| SCHEMBL29653785 | 0.87 | PRKAB2 (0.43) | BTKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-117321048-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2022133098-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SYK 727/4885BTK 255/4885KCNH2 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.